| pubmed-article:21481589 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21481589 | lifeskim:mentions | umls-concept:C1312689 | lld:lifeskim |
| pubmed-article:21481589 | lifeskim:mentions | umls-concept:C0034242 | lld:lifeskim |
| pubmed-article:21481589 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:21481589 | lifeskim:mentions | umls-concept:C0772162 | lld:lifeskim |
| pubmed-article:21481589 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:21481589 | pubmed:dateCreated | 2011-5-2 | lld:pubmed |
| pubmed-article:21481589 | pubmed:abstractText | a-FABP is indespensible in inflammation and may serve as a new potential drug target for inflammation related diseases. We have successfully designed and synthesized a series of aromatic substituted pyrazoles as new human a-FABP inhibitors. The compounds strongly bound to the hydrophobic binding pocket of a-FABP, while showed significantly lower binding affinities to the closely related homologue protein h-FABP. The most potent and selective compound 5 g bound to a-FABP with an apparent K(i) value below 1.0 nM, while did not inhibit h-FABP at 50 ?M and thus represents one of the most potent and selective a-FABP inhibitors to date. The strong binding capacity of these inhibitors was further validated by their effective blockade of inflammatory responses as determined by the production of pro-inflammatory cytokines upon LPS stimulation. Compound 5 g may serve as a lead compound for developing new effective therapeutic agent for prevention and treatment of atherosclerosis, type 2 diabetes and other inflammatory and metabolic related diseases. | lld:pubmed |
| pubmed-article:21481589 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21481589 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21481589 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21481589 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21481589 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21481589 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21481589 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21481589 | pubmed:month | May | lld:pubmed |
| pubmed-article:21481589 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:WangYuY | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:XuAiminA | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:LiuXiujieX | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:WuDonghaiD | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:LiHonglinH | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:HuangXiaoliX | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:DingKeK | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:HuiXiaoyanX | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:WangDongyeD | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:LinWanhuaW | lld:pubmed |
| pubmed-article:21481589 | pubmed:author | pubmed-author:DiaoYanyanY | lld:pubmed |
| pubmed-article:21481589 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21481589 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21481589 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:21481589 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:21481589 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21481589 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21481589 | pubmed:pagination | 2949-52 | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:meshHeading | pubmed-meshheading:21481589... | lld:pubmed |
| pubmed-article:21481589 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21481589 | pubmed:articleTitle | New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein. | lld:pubmed |
| pubmed-article:21481589 | pubmed:affiliation | Key Laboratory of Regenerative Biology and Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou 510530, PR China. | lld:pubmed |
| pubmed-article:21481589 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21481589 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:21481589 | lld:chembl |
